Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.08
-1.7000-3.28%
Post-market: 51.050.9700+1.94%19:30 EDT
Volume:487.92K
Turnover:24.66M
Market Cap:15.31B
PE:22.46
High:51.91
Open:51.91
Low:50.03
Close:51.78
52wk High:55.49
52wk Low:45.77
Shares:305.78M
Float Shares:305.78M
Volume Ratio:1.75
T/O Rate:0.16%
Dividend:2.12
Dividend Rate:4.24%
EPS(TTM):2.23
EPS(LYR):2.47
ROE:7.56%
ROA:2.91%
PB:1.63
PE(LYR):20.32

Loading ...

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

GlobeNewswire
·
Jul 22

Emera (EMA) Gets a Hold from Desjardins

TIPRANKS
·
Jul 22

Analysts Offer Insights on Utilities Companies: Emera (EMA) and Brookfield Renewable (BEPC)

TIPRANKS
·
Jul 22

J.P. Morgan Sticks to Its Hold Rating for Emera (EMA)

TIPRANKS
·
Jul 22

Emera price target raised to C$77 from C$74 at CIBC

TIPRANKS
·
Jul 21

GSK announces EMA accepted submission to update Bexsero label

TIPRANKS
·
Jul 20

BMO Capital Sticks to Its Buy Rating for Emera (EMA)

TIPRANKS
·
Jul 19

CIBC Keeps Their Hold Rating on Emera (EMA)

TIPRANKS
·
Jul 18

Emera price target raised to C$77 from C$74 at CIBC

TIPRANKS
·
Jul 18

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

TIPRANKS
·
Jul 17

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

GlobeNewswire
·
Jul 16

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

GlobeNewswire
·
Jul 16

Press Release: Correcting and Replacing Emera Declares Quarterly Dividends

Dow Jones
·
Jul 15

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

GlobeNewswire
·
Jul 14

Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar

MT Newswires Live
·
Jul 14

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

GlobeNewswire
·
Jul 13

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

TIPRANKS
·
Jul 13

Emera Keeps Quarterly Dividend at $0.7325 a Share, Payable Aug. 17 to Shareholders of Record on Aug. 3

MT Newswires Live
·
Jul 13

Press Release: Emera Declares Quarterly Dividends

Dow Jones
·
Jul 13

EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial

MT Newswires Live
·
Jul 13